Current Edition


Takeda wins US approval for new CMV treatment

Livtencity is part of the first wave of new products Takeda hopes will reposition the company as a top player in the pharmaceutical industry for …

Continue Reading →

Takeda reels in a cell therapy research partner with ‘build-to-buy’ deal

Takeda, which has made cell and gene therapy a research focus, is turning to partnerships and acquisitions to help fill out its pipeline. In addition …

Continue Reading →

Takeda wins FDA approval for targeted lung cancer drug

In the midst of a years-long makeover, Takeda is looking to new products such as Exkivity to shore up future growth and cement its place …

Continue Reading →

Johnson & Johnson has the most bucks for biopharma M&A, Astellas the easiest target: analyst

The $62 billion Takeda-Shire deal surprised everyone—and worries some—as Takeda is borrowing an enormous $31 billion to help pay for the purchase. Does it refresh the …

Continue Reading →

Takeda to Acquire Shire for $62 Billion

Takeda Pharmaceutical Company Limited announced on May 8, 2018 that it has reached agreement on the terms of an offer to acquire Shire plc in …

Continue Reading →